BioStock: Interview with Professor Rolf Ljung, member of Idogen’s SAB
Idogen’s scientific advisory board consists of knowledgeable researchers and doctors active in Idogen’s fields of interest. One of them is Rolf Ljung, senior professor of paediatrics at Lund University, who has extensive knowledge regarding haemophilia. Professor Ljung will be involved with Idogen’s first clinical study with IDO 8 in patients with severe haemophilia A who have developed antibodies against their vital treatment with coagulation factor VIII. In an interview with BioStock, Rolf Ljung talks about the upcoming study and how Idogen’s treatment can counteract the problems surrounding today’s treatment strategy.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se